Posted by Michael Rae on May 27, 2010 | Chief Science Officer's Team

The discovery of natural antibodies against beta-amyloid, the major component of the plaques that characterise Alzheimer's disease, is a promising suggestion as to the potential effectiveness of a relatively straightforward immunotherapy.

Posted by Michael Rae on May 15, 2010 | Chief Science Officer's Team

Affibodies are artificial, antibody-like proteins generated through protein engineering techniques. ZAβ3, an affibody that targets amyloid-beta (Abeta), has been shown to prevent plaque formation and neurotoxicity in animal models of Alzheimer's disease. Affibodies like ZAβ3 might have important practical advantages over antibody-based Abeta-clearing agents, making this a promising new approach.

Posted by Tanya Jones, COO on May 13, 2010 | Degradation of A2E

Daniel Kimbel joined our SENS Foundation Research Center team this week as a lab technician. Daniel will be assisting Lorenzo Albanello with our LysoSENS projects already in progress. Coming to us with a BA in Biological Sciences from Rice University, Daniel has demonstrated his commitment to pursuing the SENS objectives, by volunteering both at the research center (while it was still in Tempe) and at Arizona State University's Biodesign Institute.

Posted by Michael Rae on May 10, 2010 | Chief Science Officer's Team

Widespread optimism about the life-extension potential of calorie restriction (CR) is tempered by doubt that any significant number of people will ever adopt it as a lifestyle. However, thus far the search for "CR mimetics" – drugs that convey the same benefits on a normal calorie intake - has been fruitless. Here we review some of the prominent examples.

Posted by Michael Rae on May 2, 2010 | Chief Science Officer's Team

Unlike mouse embryonic stem cells (ESCs), human ESCs are highly prone to death after enzymatic dissociation from a growing cell cluster; as a result, researchers are forced to rely on far more laborious methods for their expansion. New research at the Scripps Institute has revealed the molecular basis for this frustrating limitation, and also uncovered two small-molecule drugs able to greatly improve the cells' survival.